Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Spironolactone

Preparation Calculator

USE IF: HFrEF (GDMT), cirrhotic ascites (± loop), resistant HTN / primary hyperaldosteronism when K⁺/renal monitoring plan exists.

AVOID IF: Hyperkalemia; severe renal impairment without monitoring; Addison's; RAAS + K⁺ supplement + MRA stack without explicit risk plan.

Spironolactone

Aldosterone antagonist (K-sparing diuretic)

AdultHFrEFAscitesDiureticK-sparingWardICUER

Indication

HFrEF β€’ Ascites β€’ Resistant HTN β€’ Primary hyperaldosteronism β€’ Selected edema

At a glance

INDICATIONS (CORE USE)

- HFrEF (mortality benefit; GDMT) - Ascites (cirrhosis; first-line diuretic) - Resistant hypertension - Primary hyperaldosteronism - Edema (selected cases)

ADULT DOSE (STANDARD)

HFrEF: 12.5–25 mg daily β†’ titrate 25–50 mg daily as tolerated Ascites: start 100 mg daily β†’ titrate (often with furosemide) Cirrhosis pathway reference: spironolactone:furosemide β‰ˆ 100:40 (protocol-guided; not universal) Resistant HTN: ~25–50 mg daily

MAX DOSE

Variable by indication (often up to 400 mg/day in ascites under specialist care)

Route

PO

PEDIATRIC DOSE

Specialist use only

Do not miss

Must-not-miss safety points

Major warning

- Hyperkalemia β†’ life-threatening arrhythmia risk - Renal impairment β†’ potassium accumulation risk - Do NOT combine with ACEi + ARB + K-sparing without clear plan (dual RAAS risk) - Cirrhotic ascites: spironolactone first-line; loop often added β€” β‰ˆ100:40 is a **protocol reference**, not mandatory universal pairing - Endocrine effects β†’ gynecomastia (clinically relevant)

Indications

Primary

  • HFrEF (mortality benefit; guideline-directed therapy)
  • Ascites (cirrhosis; first-line diuretic)

Secondary

  • Resistant hypertension
  • Primary hyperaldosteronism

Other

  • Edema states (selected cases)

Dosing

STANDARD (ADULT PO)

HFrEF: 12.5–25 mg daily β†’ titrate to 25–50 mg daily as tolerated Ascites: start 100 mg daily β†’ titrate (often with furosemide)

ADULT DOSE

Cirrhosis: β‰ˆ100:40 spironolactone:furosemide **protocol reference** (not a universal dose rule) Resistant HTN: ~25–50 mg daily

PEDIATRIC DOSE

Specialist use only

MAX DOSE

Variable by indication (often up to 400 mg/day in ascites under specialist care)

Practical Note

- Cirrhotic ascites: first-line; often + furosemide using β‰ˆ100:40 **protocol reference** β€” **not** a ratio calculator; titrate on **K⁺, Cr, weight/volume** after changes - Not a rapid decongestive for acute pulmonary edema - HF / refractory edema: loop + MRA only in **selected** pathways β€” **not** the same fixed-ratio rule as cirrhosis - With loop: ↑ AKI / hypotension / electrolyte swing risk β€” loop tends to ↓ K, spironolactone tends to ↑ K (labs drive adjustment) - Do **not** assume loop must always accompany spironolactone outside pathway-based decisions

Warnings

Clinical warnings

  • - Hyperkalemia (major risk)
  • - AKI in renal impairment
  • - Volume depletion (if over-diuresed)
  • - Loop co-therapy: ↑ AKI / hypotension / K shifts β€” **lab-guided** titration; cirrhosis β‰ˆ100:40 is a **reference strategy** only
  • - Endocrine effects (gynecomastia, menstrual irregularities)

Contraindications

  • - Hyperkalemia
  • - Severe renal impairment (high K⁺ risk)
  • - Addison's disease
  • - Known hypersensitivity

Drug interactions

  • - ACEi / ARB β†’ hyperkalemia risk
  • - NSAIDs β†’ reduced diuretic effect + AKI risk
  • - Potassium supplements β†’ hyperkalemia
  • - Other K-sparing agents β†’ dangerous combination

Special populations

Pediatrics

Specialist use only

Pregnancy

Pregnancy: avoid unless specialist-directed; fetal antiandrogenic risk per labeling.

Lactation

excreted in milk β€” risk/benefit; often avoid.

Renal impairment

High hyperkalemia risk β†’ dose cautiously or avoid depending on K⁺/Cr and co-therapy.

Hepatic impairment

Preferred in cirrhosis (ascites); add loop per pathway using β‰ˆ100:40 **protocol reference** β€” not automatic pairing for every patient.

Elderly

Higher hyperkalemia risk β†’ monitor K⁺/Cr closely after initiation and dose changes.

Administration

- PO daily dosing - Often combined with loop diuretics - Dose adjustments based on labs, not rapid symptom response

Monitoring

  • Monitor: - Potassium (K⁺) - Renal function (Cr/eGFR) - Volume status / weight
  • Recheck: - 3–7 days after initiation or dose change (reassess K⁺/Cr/weight) - Periodically thereafter (reassess volume + labs)
  • Hold if:
    - K⁺ β‰₯5.5 mmol/L (or per protocol)
    - Rising creatinine / AKI
    - Symptomatic hypotension

Overdose / toxicity

Clinical Picture

- Hyperkalemia - Hypotension - Renal dysfunction

Immediate Actions

- Stop drug - Treat hyperkalemia (calcium, insulin/glucose, protocol-based)

Antidote

- None β†’ supportive care

Decontamination

Large oral ingestion: supportive care; contact toxicology if severe symptoms.

Escalation

Refractory hyperkalemia / instability β†’ nephrology / dialysis pathway per protocol.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

- Mortality benefit in HFrEF (not just diuresis) - First-line for cirrhotic ascites - + Furosemide (when used): β‰ˆ100:40 **protocol reference** in cirrhosis pathways β€” **not** universal HF/edema logic; labs titrate, not memorized ratios

Clinical pearls

- Always think potassium first - With loop: combine for natriuresis/K dynamics in **ascites pathways** β€” still **lab-guided**; not a public ratio calculator - Most errors = missed hyperkalemia (especially with RAAS stack)

Pharmacy Tool

Preparation Calculator

Spironolactone 1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Hepatic metabolism β†’ active metabolites - Long functional duration - Renal excretion (metabolites)

Mechanism of action

- Aldosterone receptor antagonist in distal nephron

Common brand names

Saudi Arabia

Aldactone, Spirotone

Global

(placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure guidelines
  • AASLD ascites / portal hypertension guidance (where applicable)
  • KDIGO CKD blood pressure and RAAS blocker use (where applicable)
  • FDA / SFDA product labeling